| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/24/2004 | US20040122039 Pyrazolo[1,5-a]pyridines and medicines containing the same |
| 06/24/2004 | US20040122038 phenanthridin derivative containing amine or amide groups; useful for treating obesity, a feeding disorder, seizures, anxiety, diabetes, hypertension, hyperlipidemia, cancer, nasal congestion, and female or male sexual dysfunction |
| 06/24/2004 | US20040122037 Strong anti-depressant activity without being sedative; serotonin (5-HT) reuptake inhibitor activity in combination with additional alpha 2-adrenoceptor antagonist activity |
| 06/24/2004 | US20040122035 selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase-5 (PDE5); sexual disorders, cardiovascular disorders; 1-(2H-benzo[d]1,3-dioxolan-5-yl)(1,2,3,4-tetrahydro- beta -carbolin-2-yl)-2-naphthyl ketone for example |
| 06/24/2004 | US20040122034 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-1yl)acetamide |
| 06/24/2004 | US20040122032 for treating neurodegenerative disorders; mixture with other active ingredients; 1-{2-(3'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine for example; Alzheimer's disease, cerebral edema |
| 06/24/2004 | US20040122023 Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine |
| 06/24/2004 | US20040122021 High optical purity of both levoratatory and dextrorotatory forms; simple, economic synthesis |
| 06/24/2004 | US20040122020 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity |
| 06/24/2004 | US20040122017 Melanin concentrating hormone (MCH) modulators; metabolic and eating disorders |
| 06/24/2004 | US20040122013 Analogs of nocicettin |
| 06/24/2004 | US20040122010 Treatment of neuropathy |
| 06/24/2004 | US20040122004 such as (1R,2R)-N-[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]-2-(4-{[{[ethyl(2-hydroxyethyl)amino]carbonyl}(4-fluorophenyl)amino]methyl}phenyl)cyclohexanecarboxamide; for prevention/treatment of cardiovascular disorders |
| 06/24/2004 | US20040122001 Pharmaceutical compounds |
| 06/24/2004 | US20040121999 for treatment of physiological conditions/disorders arising from the hypersecretion of corticotropin-releasing factor (CRF) such as depression, anxiety, and substance abuse |
| 06/24/2004 | US20040121998 CRF antagonistic quino- and quinazolines |
| 06/24/2004 | US20040121995 such as trifluoromethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(6-trifluoromethyl-pyridine-3-sulfonyl)-cyclohexyl]-amide; for treatment/prevention of Alzheimer's disease |
| 06/24/2004 | US20040121979 Pharmaceutically active uridine esters |
| 06/24/2004 | US20040121978 Adenosine A3 receptor agonists |
| 06/24/2004 | US20040121962 Prodrugs of excitatory amino acids |
| 06/24/2004 | US20040121958 Methods of alleviating neuropathic pain |
| 06/24/2004 | US20040121956 For therapy of diseases in animals and for the control of insects that are injurious or harmful to plants or animals |
| 06/24/2004 | US20040121461 Bone marrow or cord blood cells transplanted into rat animal model comprised of demyelinated axons in order to remyelinate defective nervous system tissues; gene therapy and neurodegenerative disorders |
| 06/24/2004 | US20040121372 Comprises receptors for advanced glycation endproduct polypeptides for use in diagnosis and treatment inflammation, infection, sepsis, autoimmune, atherosclerotic and nervous system disorders |
| 06/24/2004 | US20040121028 Plant based agents as bioavailability / bioefficacy enhancers for drugs and nutraceuticals |
| 06/24/2004 | US20040120996 administering as a transdermal patch, containing oxybutynin to a patient a duration about 24 to 96 hours to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from 0.5:1 to 5:1 to treat overactive bladder |
| 06/24/2004 | US20040120925 Administering substance capable of inducing and proliferating dendritic cells or inducing gene expression of nerve growth factors; brain or nervous system disorders |
| 06/24/2004 | DE69233189T2 Heteroarylpiperidine-pyrrolidine und piperazine und ihre anwendung als antipsychotisches und analgetisches mittel Heteroarylpiperidines-pyrrolidine and piperazine and its application as an antipsychotic and analgesic medium |
| 06/24/2004 | CA2509142A1 Combination for the treatment of adhd |
| 06/24/2004 | CA2508715A1 Materials and methods relating to treatment of injury and disease to the central nervous system |
| 06/24/2004 | CA2508441A1 Propofol-containing fat emulsions |
| 06/24/2004 | CA2508004A1 Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds |
| 06/24/2004 | CA2507918A1 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia |
| 06/24/2004 | CA2506529A1 Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof |
| 06/24/2004 | CA2505335A1 Method of treating movement disorders using barbituric acid derivatives |
| 06/23/2004 | EP1430903A1 Use of proteasome inhibitors for the treatment of viral infections |
| 06/23/2004 | EP1430898A1 Receptor antagonist |
| 06/23/2004 | EP1430897A2 Opioid formulations having extended controlled release |
| 06/23/2004 | EP1430896A1 NICOTINE−CONTAINING FILM PREPARATION |
| 06/23/2004 | EP1430894A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease |
| 06/23/2004 | EP1430308A2 Screening method for different indications using bnpi and/or dnpi |
| 06/23/2004 | EP1430144A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 06/23/2004 | EP1430130A2 Nucleic acid-associated proteins |
| 06/23/2004 | EP1430120A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 06/23/2004 | EP1430114A2 Prolactin induced increase in neural stem cell numbers and therapeutical use thereof |
| 06/23/2004 | EP1430113A2 Effect of growth hormone and igf-1 on neural stem cells and therapeutic application |
| 06/23/2004 | EP1430057A2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives |
| 06/23/2004 | EP1430056A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
| 06/23/2004 | EP1430055A1 7-tert-butyl-3-(2-fluorophenyl)-6-(2h-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine for the treatment of anxiety and convulsions |
| 06/23/2004 | EP1430054A2 Purification and crystalline forms of zaleplon |
| 06/23/2004 | EP1430053A1 Chemical compounds |
| 06/23/2004 | EP1430048A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| 06/23/2004 | EP1430047A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
| 06/23/2004 | EP1430044A1 Process for the preparation of citalopram |
| 06/23/2004 | EP1430042A2 Bicyclic heterocycles as rxr ligands |
| 06/23/2004 | EP1430034A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
| 06/23/2004 | EP1430032A2 Substituted amides for the treatment of neurological disorders |
| 06/23/2004 | EP1430030A1 N-type calcium channel antagonists for the treatment of pain |
| 06/23/2004 | EP1430029A1 N-type calcium channel antagonists for the treatment of pain |
| 06/23/2004 | EP1430027A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| 06/23/2004 | EP1429844A2 Conjugated anti-psychotic drugs and uses thereof |
| 06/23/2004 | EP1429811A1 Theurapeutic tropane compounds |
| 06/23/2004 | EP1429805A2 Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass |
| 06/23/2004 | EP1429800A2 Vaccine and method for treatment of motor neurone diseases |
| 06/23/2004 | EP1429792A1 Strontium compound for treatment of sub-dermal soft tissue pain |
| 06/23/2004 | EP1429788A2 Use of mannosamine derivatives for the stimulation of neurite growth |
| 06/23/2004 | EP1429787A1 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder |
| 06/23/2004 | EP1429784A2 High throughput screening assays using fatty acid synthetic enzymes |
| 06/23/2004 | EP1429776A2 Tricyclic indole derivatives as 5-ht ligands |
| 06/23/2004 | EP1429773A1 Process for making substituted pyrazoles |
| 06/23/2004 | EP1429771A2 Bicyclic compounds as inhibitors of chemokine binding to us28 |
| 06/23/2004 | EP1429770A1 New formulations and use thereof |
| 06/23/2004 | EP1429769A1 New formulations and use thereof |
| 06/23/2004 | EP1429767A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage |
| 06/23/2004 | EP1429762A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
| 06/23/2004 | EP1429761A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 06/23/2004 | EP1429760A1 Novel combination |
| 06/23/2004 | EP1429752A1 Neuroprotective treatment methods using selective inos inhibitors |
| 06/23/2004 | EP1429730A2 Opioid formulations having reduced potential for abuse |
| 06/23/2004 | EP1429727A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 06/23/2004 | EP1429723A1 Treating effects of excessive reactive oxygen species |
| 06/23/2004 | EP1429617A2 Methods for sterilizing preparations of digestive enzymes |
| 06/23/2004 | EP1429602A1 Methods for treating disorders using plant extracts |
| 06/23/2004 | EP1372392A4 Nicotine-containing oral dosage form |
| 06/23/2004 | EP1353906B1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
| 06/23/2004 | EP1263932A4 Embryonic stem cells and neural progenitor cells derived therefrom |
| 06/23/2004 | EP1252157B1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 06/23/2004 | EP1251848B1 Gyrase inhibitors and uses thereof |
| 06/23/2004 | EP1246817B1 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives |
| 06/23/2004 | EP1239832B1 Suspension comprising oxcarbazepine |
| 06/23/2004 | EP1237851A4 SALTS OF i Cis /i -4-CYANO-4- 3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
| 06/23/2004 | EP1230227B1 Benzoxa-and benzothiazolyl sulfamates and their use as steroid sulfatase inhibitors |
| 06/23/2004 | EP1171573B1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 06/23/2004 | EP1171146B1 Pharmaceutical compositions containing selegiline and ginkgo biloba extract useful for treating dementia |
| 06/23/2004 | EP1124556B1 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders |
| 06/23/2004 | EP1076644B1 N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| 06/23/2004 | EP1066283B1 Substituted indolealkanoic acids |
| 06/23/2004 | EP0999839B1 Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| 06/23/2004 | EP0973516B1 Use of halo and/or nitro-substituted flavonoids as anxyolitics |
| 06/23/2004 | CN1507491A Apoptosis promoter and inhibitor interacting with CGI-94 and method of screening the same |